MorphoSys AG (MOR) Given a €76.00 Price Target at Commerzbank Ag
MorphoSys AG (ETR:MOR) has been given a €76.00 ($90.48) price target by Commerzbank Ag in a report issued on Thursday. The firm currently has a “buy” rating on the stock.
A number of other research firms have also weighed in on MOR. Berenberg Bank set a €68.00 ($80.95) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Wednesday, August 16th. Independent Research GmbH set a €77.00 ($91.67) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Monday, August 7th. Deutsche Bank AG set a €90.00 ($107.14) target price on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Monday, August 7th. J P Morgan Chase & Co set a €62.00 ($73.81) target price on shares of MorphoSys AG and gave the stock a “neutral” rating in a report on Friday, August 4th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) target price on shares of MorphoSys AG and gave the stock a “neutral” rating in a report on Friday, August 4th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. MorphoSys AG presently has an average rating of “Buy” and an average target price of €69.57 ($82.82).
MorphoSys AG (ETR MOR) opened at 59.90 on Thursday. The stock’s market cap is €1.74 billion. The firm has a 50-day moving average price of €60.78 and a 200-day moving average price of €58.18. MorphoSys AG has a 52 week low of €35.72 and a 52 week high of €70.90.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/31/morphosys-ag-mor-given-a-76-00-price-target-at-commerzbank-ag.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.